The Concerta brand and generic market had US sales of approximately USD 1.159bn MAT for the most recent twelve months ending in June 2020 according to IQVIA Health.
Dr. Reddy's Methylphenidate Hydrochloride Extended-Release Tablets, USP are available in strengths of 18 mg, 27 mg, 36 mg, and 54 mg tablets in bottle count sizes of 100.
Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.
Dr. Reddy's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe.
Its major markets include USA, India, Russia and CIS countries, and Europe.
Peak Pharma Commercial Partners establishes Resilia Pharmaceuticals and starts operations
Nephron Pharmaceuticals Corporation receives USFDA approval over Ketorolac Tromethamine Injection
Amring gains global rights to LYSTEDA
Troy Medicare Closes USD 10m Series B Led by AXA Venture Partners
Breckenridge wins final FDA approval for Pomalidomide Capsules ANDA
Amneal Receives Abbreviated New Drug Application Approval for Acyclovir Cream, 5%
Cipla reports sharp rise in demand for COVID-19 drug remdesivir in India
Sandoz ships pantoprazole sodium to Civica Rx
Russia's Pharmasyntez seeks permission to produce COVID-19 drug without patent